AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)
Latest Information Update: 06 Jan 2025
At a glance
- Drugs Lecanemab (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms A3; A45; AHEAD; AHEAD 3-45
- Sponsors Eisai Inc
Most Recent Events
- 04 Dec 2024 According to a BioArctic media release, this 4-year study is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health and Eisai.
- 31 Oct 2024 According to a BioArctic media release, patient enrollment completed in October 2024.
- 31 Oct 2024 Status changed from recruiting to active, no longer recruiting, according to a BioArctic media release.